Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)

1.520 -0.080 (-5.00%) As of 03:51PM HKT. Market open.

Jacobio Pharmaceuticals Group Co., Ltd.

Building 8
No.105 Jinghai 3rd Road Beijing Economic-Technological Development Area
Beijing
China

https://www.jacobiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 301

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yinxiang Wang	Executive Chairman & CEO	3.41M	N/A	1965
Ms. Xiaojie Wang	Executive Director & President of Administration	2.54M	N/A	1965
Ms. Yunyan Hu	Executive VP & Executive Director	2.54M	N/A	1962
Ms. Tao Yang	Vice President of Human Resources	N/A	N/A	N/A
Dr. Andrea Wang-Gillam M.D., Ph.D.	Executive VP, Chief Medical Officer and Global Head of R&D	N/A	N/A	1971
Ms. Yanping Wang	Executive Vice President of Non-Clinical R&D	N/A	N/A	N/A
Dr. Haijun Wang	Senior Vice President of Information & Data Management	N/A	N/A	N/A
Dr. Wei Long	Head of Drug Discovery	N/A	N/A	N/A
Ms. Yuli Ding	Executive Vice President of Clinical Development	N/A	N/A	N/A
Ms. Qing Xue	Joint Company Secretary	N/A	N/A	1989

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. The company's drug development programs include Glecirasib (JAB-21822), a KRAS G12C inhibitor currently under multiple stage studies for indications, including NSCLC, PDAC, CRC and other solid tumors; JAB-3068, an SHP2 inhibitor approved by the FDA to enter clinical development for the treatment of esophageal cancer, including esophageal squamous cell carcinoma; and JAB-3312, an SHP2 inhibitor with multiple indications, such as KRAS G12C mut NSCLC under Phase III pivotal study, and Osimertinib progressed NSCLC under Phase I study, as well as NSCLC, HNSCC, and ESCC under Phase IIa studies. It also develops JAB-23E73 currently under IND-enabling studies for targeting multiple KRAS mutants indicated for PDAC, CRC, and NSCLC; JAB-BX300, a self-developed LIF mAb, under IND study indicated for the treatment of solid tumors; JAB-22000, a small-molecule KRAS G12D inhibitor, under lead optimization study indicated for PDAC, CRC, and NSCLC treatments; and JAB-8263, a Bromodomain and Extra-Terminal motif (BET) inhibitor, under Phase I studies indicated for MF, AML, and solid tumor. In addition, the company is involved in the development of JAB-2485, an Aurora Kinase A inhibitor, under Phase I study indicated for the treatment of solid tumors; JAB-24114, a glutamine-utilizing enzyme inhibitor under IND study indicated for the treatment of solid tumors; and JAB-30355, an orally bioavailable small molecule activator under IND study for the treatment of patients with locally advanced or metastatic solid tumors. It has a license and collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. The company was founded in 2015 and is headquartered in Beijing, China.

Corporate governance

Jacobio Pharmaceuticals Group Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.